Protagonist Therapeutics Inc(PTGX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

PTGX Protagonist Therapeutics Inc

已收盘 05-06 16:00:00 EDT

103.97

+4.76

+4.80%

盘后103.97

+0.000.00%

19:52 EDT

最高105.03	最低98.95	成交量98.99万
今开103.00	昨收99.21	日振幅6.12%
总市值66.86亿	流通市值44.87亿	总股本6,431万
成交额1.02亿	换手率2.29%	流通股本4,315万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"PTGX","market":"US","secType":"STK","nameCN":"Protagonist Therapeutics Inc","latestPrice":103.97,"timestamp":1778097600000,"preClose":99.21,"halted":0,"volume":989855,"hourTrading":{"tag":"盘后","latestPrice":103.97,"preClose":103.97,"latestTime":"19:52 EDT","volume":29206,"amount":3036466.8,"timestamp":1778111578917,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.04797903437153518,"floatShares":43154809,"shares":64305185,"eps":-2.05,"marketStatus":"已收盘","change":4.76,"latestTime":"05-06 16:00:00 EDT","open":103,"high":105.025,"low":98.95,"amount":102120875.61105,"amplitude":0.061234,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.05,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1778140800000},"marketStatusCode":5,"adr":0,"adrRate":0,"listingDate":1470888000000,"exchange":"NASDAQ","adjPreClose":99.21,"preHourTrading":{"tag":"盘前","latestPrice":103.69,"preClose":99.21,"latestTime":"09:29 EDT","volume":398,"amount":41181.069552,"timestamp":1778074199999,"change":4.48,"changeRate":0.045157,"amplitude":0.056547},"postHourTrading":{"tag":"盘后","latestPrice":103.97,"preClose":103.97,"latestTime":"19:52 EDT","volume":29206,"amount":3036466.8,"timestamp":1778111578917,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":2.013882,"impliedVol":0.4537,"impliedVolPercentile":0.2709},"requestUrl":"/m/hq/s/PTGX","defaultTab":"news","newsList":[{"id":"1124926857","title":"Protagonist股价盘前涨4% 与强生合作口服银屑病药获FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1124926857","media":"美股速递","labels":["corporation","productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1124926857?lang=zh_cn&edition=full","pubTime":"2026-03-18 20:19","pubTimestamp":1773836390,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局正式批准了Protagonist Therapeutics与强生公司联合开发的口服银屑病治疗药物，受此消息推动，Protagonist股价在盘前交易中上涨约4%。这一监管批准标志着两家公司在自身免疫疾病治疗领域取得重要突破。银屑病作为一种慢性免疫介导的皮肤病，全球患者人数超过1.25亿，其中中重度患者占比约20%。Protagonist作为一家专注于肽类药物开发的生物技术公司，与制药巨头强生的合作体现了行业内的资源互补模式。除了Protagonist股价上涨外，强生股价也呈现温和上涨态势。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0795875086.SGD","LU2129689514.USD","LU1057294990.SGD","LU1032466523.USD","LU2750360997.AUD","LU1074936037.SGD","LU0124676726.USD","LU1244550494.USD","IE00BKVL7J92.USD","LU0792757196.USD","IE00B19Z3581.USD","LU2089984988.USD","LU1066051225.USD","LU0070217475.USD","LU0058720904.USD","SG9999002224.SGD","LU1929549753.HKD","LU1221951129.SGD","LU1732800096.USD","IE00BSNM7G36.USD","LU1894683348.USD","LU1032955483.USD","LU1732799900.SGD","LU1585245621.USD","BK4504","LU2112291526.USD","IE00BVYPNV92.GBP","JNJ","LU1430594728.SGD","BK4559","IE000M9KFDE8.USD","LU0345770308.USD","BK4139","LU1066053197.SGD","IE00BLSP4239.USD","IE00BJJMRZ35.SGD","LU1894683264.USD","IE00B42XCP33.USD","LU0098860793.USD","LU0432979614.USD","LU0985320562.USD","LU0689626769.HKD","LU1244550577.SGD","LU2129689431.USD","LU2505996681.GBP","IE00B2B36J28.USD","SG9999002232.USD","PTGX","BK4585","LU1914381329.SGD","IE00BJT1NW94.SGD","LU2592432038.USD","IE00BLSP4452.SGD","IE00BZ1G4Q59.USD","LU0345769631.USD","LU1674673428.USD","IE00BGHQF631.EUR","LU0683600562.USD","IE00B19Z3B42.SGD","LU0345770993.USD","LU0912757837.SGD","LU1935042991.SGD","LU1983299246.USD","LU0345769128.USD","LU1674673691.USD","BK4532","LU1196500208.SGD","LU1496350502.SGD","LU1280957306.USD","LU2430703095.HKD","BK4592","LU2430703251.USD","IE0002141913.USD","IE00BDGV0183.EUR","LU0203347892.USD","LU1718418525.SGD","LU1023059063.AUD","LU0320765646.SGD","LU2347655156.SGD","LU0234572021.USD","LU0795875169.SGD","LU0889566641.SGD","BK4534","IE00B7SZLL34.SGD","LU2471134879.HKD","LU1244550221.USD","LU2505996509.AUD","LU2133065610.SGD","LU2129689605.HKD","LU2602419157.SGD","LU1506573853.SGD","LU1061106388.HKD","LU1066051811.HKD","LU1059921491.USD","IE0009355771.USD","LU0882574055.USD","IE00BVYPNW00.USD","LU0203345920.USD","IE0002270589.USD","LU0289739699.SGD","IE00BFTCPJ56.SGD","LU2471134952.CNY","LU1066051498.USD","SG9999001440.SGD","LU2750360641.GBP","LU1162221912.USD","LU2471134796.USD","IE0001KFT4U8.USD","LU1261432733.SGD","LU2471134523.USD","BK4568","BK4581","IE00B3PB1722.GBP","LU0234570918.USD","IE00B4R5TH58.HKD","IE00B1BXHZ80.USD","IE00B3T34201.USD","LU0114720955.EUR","LU1267930813.SGD","BK4533","LU2468319806.SGD","BK4007","LU1221951046.USD","IE00BBT3K403.USD","LU2430703178.SGD","LU0122379950.USD","BK4550","IE00BFXG1179.USD","LU0640476718.USD","LU0466842654.USD","BK4588","IE0034235303.USD","LU1778281490.HKD","IE00BN8TJ469.HKD","LU0787776722.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137079203","title":"武田与Protagonist宣布美国FDA受理Rusfertide新药申请并授予优先审评资格，该药有望成为真性红细胞增多症的首创疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=1137079203","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1137079203?lang=zh_cn&edition=full","pubTime":"2026-03-02 15:04","pubTimestamp":1772435074,"startTime":"0","endTime":"0","summary":"武田制药与Protagonist Therapeutics Inc（纳斯达克代码：PTGX）共同宣布，美国食品药品监督管理局（FDA）已正式受理其联合研发药物Rusfertide的新药申请（NDA），并授予其优先审评资格。Rusfertide作为一种潜在的首创疗法，旨在用于治疗真性红细胞增多症患者。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTGX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171790316","title":"Protagonist Therapeutics将在第二季度启动的90天窗口期内退出与武田就Rusfertide达成的50:50利润分成协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1171790316","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1171790316?lang=zh_cn&edition=full","pubTime":"2026-02-26 05:41","pubTimestamp":1772055674,"startTime":"0","endTime":"0","summary":"生物制药公司Protagonist Therapeutics Inc（纳斯达克代码：PTGX）宣布，计划在预计于今年第二季度开放的90天选择窗口期内，行使其权利，退出与合作伙伴武田制药就实验性药物Rusfertide所签订的50:50利润分成安排。\n此举意味着Protagonist Therapeutics将重新获得Rusfertide在全球范围内的全部开发和商业化权利。Rusfertide是一种用于治疗真性红细胞增多症等血液疾病的在研疗法。公司表示，这一战略性决策旨在最大化该药物的潜在价值，并为其未来发展提供更大的灵活性。\n","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PTGX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144111389","title":"Protagonist Therapeutics公司：Rusfertide新药申请已提交至美国FDA，有望年内获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=1144111389","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1144111389?lang=zh_cn&edition=full","pubTime":"2026-02-26 05:41","pubTimestamp":1772055673,"startTime":"0","endTime":"0","summary":"Protagonist Therapeutics公司近日宣布，其核心产品Rusfertide的新药申请（NDA）已正式提交至美国食品药品监督管理局（FDA）。此次提交标志着该药物在监管审批流程中迈出关键一步。\n若审批进展顺利，Rusfertide有望在今年内获得上市批准并实现商业发布。这一进展对推动公司产品管线发展具有重要意义，也为相关患者群体带来新的治疗希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTGX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158797570","title":"武田与Protagonist宣布提交Rusfertide治疗真性红细胞增多症的新药申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1158797570","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1158797570?lang=zh_cn&edition=full","pubTime":"2026-01-05 20:01","pubTimestamp":1767614517,"startTime":"0","endTime":"0","summary":"武田制药与Protagonist Therapeutics Inc宣布，双方已正式向监管机构提交Rusfertide用于治疗真性红细胞增多症的新药申请。该申请标志着这一创新疗法在临床开发进程中迈出关键一步，有望为PV患者提供新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTGX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135288143","title":"Protagonist Therapeutics第三季度每股收益为-0.62美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1135288143","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1135288143?lang=zh_cn&edition=full","pubTime":"2025-11-20 01:02","pubTimestamp":1763571763,"startTime":"0","endTime":"0","summary":"11月6日 - Protagonist Therapeutics第三季度净收入为-3933.9万美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PTGX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518746288","title":"加拿大蒙特利尔银行：维持Protagonist Therapeutics(PTGX.US)评级，由优于大市调整至优于大市评级, 目标价由62.00美元调整至72.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2518746288","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518746288?lang=zh_cn&edition=full","pubTime":"2025-03-11 20:51","pubTimestamp":1741697512,"startTime":"0","endTime":"0","summary":"加拿大蒙特利尔银行：维持Protagonist Therapeutics(PTGX.US)评级，由优于大市调整至优于大市评级, 目标价由62.00美元调整至72.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/11205148668541.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BMO","PTGX","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518139278","title":"Protagonist Therapeutics, Inc.股价飙升29.07% 市值涨8.83亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518139278","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518139278?lang=zh_cn&edition=full","pubTime":"2025-03-10 21:31","pubTimestamp":1741613503,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日21时31分，Protagonist Therapeutics, Inc.股票出现异动，股价大幅拉升29.07%。Protagonist Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.59%。其相关个股中，Checkpoint Therapeutics, Inc.、Trevi Therapeutics, Inc.、Scisparc Ltd.涨幅较大，Biodexa Pharmaceuticals Plc、Scisparc Ltd.、Dogwood Therapeutics, Inc.较为活跃，换手率分别为1875.52%、391.16%、49.73%，振幅较大的相关个股有Xencor, Inc.、Seer, Inc.、Y-Mabs Therapeutics, Inc.，振幅分别为99.13%、98.72%、94.67%。Protagonist Therapeutics, Inc.公司简介：Protagonist Therapeutics Inc 是一家临床阶段的生物制药公司，拥有专有技术平台，能够发现和开发新型受限肽候选药物以满足医疗需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310213144abf2fc01&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310213144abf2fc01&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PTGX","LENZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516676946","title":"Protagonist Therapeutics(PTGX.US)与武田(Takeda)3期研究VERIFY初步结果积极 助力PV患者摆脱放血治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=2516676946","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516676946?lang=zh_cn&edition=full","pubTime":"2025-03-04 21:06","pubTimestamp":1741093579,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，Protagonist Therapeutics与武田今天宣布了3期研究VERIFY的初步积极结果。PV患者发生致命性心血管事件和血栓形成的风险增加。当前治疗指南建议，将血容量降低至45%以下是PV患者的主要治疗目标。在20至32周期间，rusfertide治疗组的临床应答率为77%，显著高于安慰剂组的33%，试验主要终点定义为患者无需接受放血治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1257725.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4139","PTGX","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516517651","title":"HC Wainwright & Co.：重申Protagonist Therapeutics(PTGX.US)评级，由买入调整至买入评级, 目标价由54.00美元调整至54.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2516517651","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516517651?lang=zh_cn&edition=full","pubTime":"2025-03-04 01:55","pubTimestamp":1741024555,"startTime":"0","endTime":"0","summary":"HC Wainwright & Co.：重申Protagonist Therapeutics(PTGX.US)评级，由买入调整至买入评级, 目标价由54.00美元调整至54.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/04015548498810.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LENZ","PTGX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107486116","title":"异动解读 | 主角疗法血癌新药临床试验获得重大进展,股价盘中大涨12.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=1107486116","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1107486116?lang=zh_cn&edition=full","pubTime":"2025-03-03 22:34","pubTimestamp":1741012469,"startTime":"0","endTime":"0","summary":"Protagonist Therapeutics Inc公司盘中股价大涨12.13%,引发市场强烈关注。这与公司新一代血癌治疗药物芦伐他汀在临床3期试验中取得积极进展密切相关。数据显示,77%的患者对该药物产生有效反应,远高于安慰剂组33%的有效率。这一积极的临床试验结果,对于PTGX新药的上市前景带来了利好预期,也为公司长期发展注入了强劲动力。总的来看,芦伐他汀新药为PTGX公司未来商业化前景带来了极大期待,推动当日股价出现大幅上涨。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["PTGX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516634023","title":"Protagonist Therapeutics, Inc.盘中异动 快速上涨9.51%报41.17美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516634023","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516634023?lang=zh_cn&edition=full","pubTime":"2025-03-03 22:31","pubTimestamp":1741012269,"startTime":"0","endTime":"0","summary":"北京时间2025年03月03日22时31分，Protagonist Therapeutics, Inc.股票出现异动，股价急速拉升9.51%。Protagonist Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.21%。Protagonist Therapeutics, Inc.公司简介：Protagonist Therapeutics Inc 是一家临床阶段的生物制药公司，拥有专有技术平台，能够发现和开发新型受限肽候选药物以满足医疗需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303223109abe632bb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303223109abe632bb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","PTGX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132922680","title":"异动解读 | 主角疗法血癌药物晚期临床有利数据推动盘前股价大涨11.73%","url":"https://stock-news.laohu8.com/highlight/detail?id=1132922680","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1132922680?lang=zh_cn&edition=full","pubTime":"2025-03-03 22:04","pubTimestamp":1741010658,"startTime":"0","endTime":"0","summary":"Protagonist Therapeutics Inc(PTGX)3月3日盘前股价大涨11.73%,主要受到其血癌药物芦伐他汀在晚期临床试验中取得积极进展的利好推动。\nPTGX和武田公司联合公布,其治疗一种罕见血癌--多发性红细胞症--的芦伐他汀药物在临床3期试验中达到了主要终点,77%的患者对该药物产生有效反应,远高于安慰剂组33%的有效率。\n这一利好数据给PTGX的长期发展前景带来了信心,市场看好该药物通过审批上市后的商业前景,因此在盘前推动股价大涨。但同时也没有证据显示该药物会增加患者罹患癌症的风险,这一点有助于减少市场的忧虑。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"异动解读 | 主角疗法血癌药物晚期临床有利数据推动盘前股价大涨11.73%","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["PTGX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125824802","title":"异动解读 | 高盛下调目标价,Protagonist Therapeutics盘中大跌6.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=1125824802","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1125824802?lang=zh_cn&edition=full","pubTime":"2025-02-25 00:32","pubTimestamp":1740414745,"startTime":"0","endTime":"0","summary":"生物技术公司Protagonist Therapeutics(PTGX.US)今日盘中大跌6.19%,引发广泛关注。\n\n分析人士认为,造成该股大跌的主要原因是高盛下调了该公司的目标价。具体而言,高盛维持了Protagonist对该公司评级为\"中性\",但将其12个月目标价从之前的43美元调降至38美元。\n\n目标价的下调 ,反映出分析师对Protagonist Therapeutics未来业绩的乐观程度有所降低。虽然高盛未做出实质性评级调整,但下调目标价仍让市场对该公司前景的信心受到打击,导致投资者抛售该股,股价大幅下跌。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"异动解读 | 高盛下调目标价,Protagonist Therapeutics盘中大跌6.19%","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["PTGX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514477683","title":"高盛：维持Protagonist Therapeutics(PTGX.US)评级，由中性调整至中性评级, 目标价由43.00美元调整至38.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2514477683","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514477683?lang=zh_cn&edition=full","pubTime":"2025-02-25 00:25","pubTimestamp":1740414342,"startTime":"0","endTime":"0","summary":"高盛：维持Protagonist Therapeutics(PTGX.US)评级，由中性调整至中性评级, 目标价由43.00美元调整至38.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/25002548356355.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LENZ","PTGX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514775425","title":"Protagonist Therapeutics, Inc.2024财年实现净利润2.75亿美元，同比增加448.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514775425","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514775425?lang=zh_cn&edition=full","pubTime":"2025-02-25 00:00","pubTimestamp":1740412842,"startTime":"0","endTime":"0","summary":"2月25日，Protagonist Therapeutics, Inc.公布财报，公告显示公司2024财年净利润为2.75亿美元，同比增加448.28%；其中营业收入为4.34亿美元，同比增加623.33%，每股基本收益为4.47美元。从资产负债表来看，Protagonist Therapeutics, Inc.总负债71.54百万美元，其中短期债务510000.00美元，资产负债比为0.11，流动比率为0.13。机构评级：截至2025年2月25日，当前有11家机构对Protagonist Therapeutics, Inc.目标价做出预测，其中目标均价为58.73美元，其中最低目标价为38.00美元，最高目标价为68.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225000056abdb2325&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225000056abdb2325&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","PTGX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513295963","title":"Protagonist Therapeutics(PTGX.US)：2024年Q4财报实现营收1.706亿美元，前值为6000万美元，预期值为5352万美元；每股收益为1.98美元，前值为0.44美元，预期值为1.03美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2513295963","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513295963?lang=zh_cn&edition=full","pubTime":"2025-02-21 22:23","pubTimestamp":1740147781,"startTime":"0","endTime":"0","summary":"Protagonist Therapeutics(PTGX.US)：2024年Q4财报实现营收1.706亿美元，前值为6000万美元，预期值为5352万美元；每股收益为1.98美元，前值为0.44美元，预期值为1.03美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/21222348320009.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["PTGX","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2508468600","title":"小摩：维持Protagonist Therapeutics(PTGX.US)评级，由增持调整至增持评级, 目标价由51.00美元调整至53.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2508468600","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2508468600?lang=zh_cn&edition=full","pubTime":"2025-02-04 23:13","pubTimestamp":1738681987,"startTime":"0","endTime":"0","summary":"小摩：维持Protagonist Therapeutics(PTGX.US)评级，由增持调整至增持评级, 目标价由51.00美元调整至53.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/04231347949902.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LENZ","PTGX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2506309388","title":"Protagonist Therapeutics, Inc.盘中异动 股价大涨5.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2506309388","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2506309388?lang=zh_cn&edition=full","pubTime":"2025-01-27 23:28","pubTimestamp":1737991687,"startTime":"0","endTime":"0","summary":"北京时间2025年01月27日23时28分，Protagonist Therapeutics, Inc.股票出现异动，股价快速上涨5.07%。Protagonist Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为1.25%。其相关个股中，Akero Therapeutics, Inc.、Onconetix, Inc.、89Bio, Inc.涨幅较大，Onconetix, Inc.、Dogwood Therapeutics, Inc.、Evaxion Biotech As较为活跃，换手率分别为1816.76%、236.67%、201.50%，振幅较大的相关个股有Onconetix, Inc.、Dogwood Therapeutics, Inc.、Conduit Pharmaceuticals Inc C/Wts 22/09/2028，振幅分别为85.35%、69.21%、65.16%。Protagonist Therapeutics, Inc.公司简介：Protagonist Therapeutics Inc 是一家临床阶段的生物制药公司，拥有专有技术平台，能够发现和开发新型受限肽候选药物以满足医疗需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250127232808a23176bf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250127232808a23176bf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","PTGX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2503915761","title":"Protagonist Therapeutics, Inc.盘中异动 急速下挫5.61%","url":"https://stock-news.laohu8.com/highlight/detail?id=2503915761","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2503915761?lang=zh_cn&edition=full","pubTime":"2025-01-16 22:58","pubTimestamp":1737039513,"startTime":"0","endTime":"0","summary":"北京时间2025年01月16日22时58分，Protagonist Therapeutics, Inc.股票出现异动，股价快速下挫5.61%。Protagonist Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.83%。Protagonist Therapeutics, Inc.公司简介：Protagonist Therapeutics Inc 是一家临床阶段的生物制药公司，拥有专有技术平台，能够发现和开发新型受限肽候选药物以满足医疗需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250116225833a22465c4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250116225833a22465c4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","PTGX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.protagonist-inc.com","stockEarnings":[{"period":"1week","weight":-0.0198},{"period":"1month","weight":-0.044},{"period":"3month","weight":0.191},{"period":"6month","weight":0.2435},{"period":"1year","weight":1.2405},{"period":"ytd","weight":0.1359}],"compareEarnings":[{"period":"1week","weight":0.017},{"period":"1month","weight":0.1036},{"period":"3month","weight":0.0548},{"period":"6month","weight":0.0798},{"period":"1year","weight":0.2844},{"period":"ytd","weight":0.0614}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Protagonist Therapeutics, Inc.在特拉华州注册成立于2006年8月22日，总部位于加利福尼亚州米尔皮塔斯。该公司是一家生物制药公司，其基于多肽的新化学实体rusfertide和JNJ-2113（原名PN-235）处于不同的开发阶段，均源自专有的发现技术平台。该公司的临床项目分为两大类疾病：（一）血液学和血液疾病，以及（二）炎症和免疫调节疾病。","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.030975},{"month":2,"riseRate":0.5,"avgChangeRate":0.004927},{"month":3,"riseRate":0.5,"avgChangeRate":0.077907},{"month":4,"riseRate":0.2,"avgChangeRate":-0.1188},{"month":5,"riseRate":0.7,"avgChangeRate":0.185904},{"month":6,"riseRate":0.777778,"avgChangeRate":0.09374},{"month":7,"riseRate":0.555556,"avgChangeRate":0.002773},{"month":8,"riseRate":0.777778,"avgChangeRate":0.16209},{"month":9,"riseRate":0.5,"avgChangeRate":0.00523},{"month":10,"riseRate":0.4,"avgChangeRate":0.039581},{"month":11,"riseRate":0.6,"avgChangeRate":0.076941},{"month":12,"riseRate":0.5,"avgChangeRate":0.014044}],"exchange":"NASDAQ","name":"Protagonist Therapeutics Inc","nameEN":"Protagonist Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Protagonist Therapeutics Inc(PTGX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Protagonist Therapeutics Inc(PTGX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Protagonist Therapeutics Inc,PTGX,Protagonist Therapeutics Inc股票,Protagonist Therapeutics Inc股票老虎,Protagonist Therapeutics Inc股票老虎国际,Protagonist Therapeutics Inc行情,Protagonist Therapeutics Inc股票行情,Protagonist Therapeutics Inc股价,Protagonist Therapeutics Inc股市,Protagonist Therapeutics Inc股票价格,Protagonist Therapeutics Inc股票交易,Protagonist Therapeutics Inc股票购买,Protagonist Therapeutics Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Protagonist Therapeutics Inc(PTGX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Protagonist Therapeutics Inc(PTGX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}